RxDoctor Payments DataLook up a doctor →

Keisha Ritter

Family · Brandywine, MDNPI 1750784419

Payments from drug & device makers

$12,397in general payments, 2019–2025

Across 461 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$784
  • Johnson & Johnson$762
  • Merck$640
  • Pfizer$626
  • Incyte Corporation$493
  • plus $6K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis58$2,671
AstraZeneca(2 entities)34$784
Johnson & Johnson(2 entities)28$762
Merck31$640
Pfizer29$626
Incyte Corporation19$493
Sanofi14$415
Daiichi Sankyo Inc.11$318
Amgen11$286
Seagen Inc.14$270
Genentech USA, Inc.11$253
Bayer11$247
Pharmaessentia USA Corporation8$245
Astellas Pharma US Inc7$228
Takeda Pharmaceuticals U.S.A., Inc.8$218
Exelixis Inc.8$216
AVEO Pharmaceuticals, Inc.5$194
Eisai Inc.9$191
AbbVie8$187
Stemline Therapeutics Inc.6$165
Lilly USA, LLC8$158
Beone Medicines USA, Inc.5$145
Pharmacyclics LLC, An Abbvie Company6$144
Beigene USA, Inc.5$124
GSK5$121
Pharmacosmos Therapeutics Inc.5$116
E.r. Squibb & Sons, L.L.C.6$111
Regeneron Healthcare Solutions, Inc.4$109
Ipsen Biopharmaceuticals, Inc4$104
ADC Therapeutics America, Inc.4$101
Kyowa Kirin, Inc.5$94
Sobi, Inc4$87
Sanofi-aventis U.S. LLC1$85
Sumitomo Pharma America, Inc.3$78
Array Biopharma Inc4$76
Rigel Pharmaceuticals, Inc.3$75
Morphosys, US Inc.3$68
Puma Biotechnology, Inc.4$67
Gilead(2 entities)3$64
Blueprint Medicines Corporation3$62
EMD Serono, Inc.3$62
Novocure Inc.2$59
Coherus Oncology, Inc.3$57
Deciphera Pharmaceuticals Inc.3$56
Mirati Therapeutics, Inc.2$53
Myovant Sciences Inc.2$47
Spectrum Pharmaceuticals Inc.2$45
Tersera Therapeutics LLC2$44
Bristol Myers Squibb2$44
Caris MPI, Inc.2$35
Blue Earth Diagnostics1$35
Genmab U.S., Inc.1$34
Boehringer Ingelheim1$31
Taiho Oncology, Inc.2$30
Agios Pharmaceuticals, Inc.1$30
Alnylam Pharmaceuticals Inc.2$30
Lundbeck LLC1$27
Dexcom, Inc.1$26
Immunogen, Inc.1$24
G1 Therapeutics, Inc.1$24

How this compares

$12,397 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland →

Medicare billing

Part B allowed, 2024
$128,012
Medicare patients
98
Services billed
4,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Brandywine

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →